Journal: World Journal of Surgical Oncology
Article Title: The downregulation of NCXs is positively correlated with the prognosis of stage II–IV colon cancer
doi: 10.1186/s12957-021-02284-5
Figure Lengend Snippet: Expression of NCX1, NCX2, and NCX3 in primary and metastatic sites. (×400). a – c In the primary tumor site, heteromorphism of the glands was very obvious, and the degree of differentiation was moderate, as determined. The expression strengths of NCX1 ( a ), NCX2 ( b ), and NCX3 ( c ) in colonic malignant glands decreased more obviously. d – f The expression intensity of NCXs at lymph node metastasis sites decreased more significantly than that at primary sites. d The expression of NCX1 was weak in malignant glands compared with lymph node metastasis sites. There were nearly no positive NCX2 ( e ) and NCX3 ( f ) cells at the lymph node metastasis sites. g – i The expression of NCXs in normal hepatocytes (black arrows) at liver metastasis sites was obvious, and the strength of NCX1 staining ( g ; white arrow) was higher than that of NCX2 ( h ; white arrow) and NCX3 ( i ; white arrow). NCXs were almost not expressed in malignant glands ( g , h , i ; white arrows). The IOD is represented by a histogram ( j – l )
Article Snippet: The sections were incubated with mouse anti-NCX1 monoclonal antibody (1:400, Abcam, Cambridge, UK), rabbit anti-NCX2 polyclonal antibody (1: 200, Bioss, Beijing, P.R.
Techniques: Expressing, Staining